Experienced in Primary Immunodeficiency (PID)

Dr. Miguel Islas

Hematology Oncology | Hematology | Oncology
St Elizabeth Medical Center, Inc
711 Medical Village Dr, 
Edgewood, KY 
Experienced in Primary Immunodeficiency (PID)
St Elizabeth Medical Center, Inc
711 Medical Village Dr, 
Edgewood, KY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Miguel Islas is a Hematologist Oncology specialist and a Hematologist in Edgewood, Kentucky. Dr. Islas is rated as an Experienced provider by MediFind in the treatment of Primary Immunodeficiency (PID). His top areas of expertise are Non-Hodgkin Lymphoma, Multiple Myeloma, B-Cell Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant.

His clinical research consists of co-authoring 5 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in OH
Hospital Affiliations
St Elizabeth Florence
St Elizabeth Edgewood
St Elizabeth Grant
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Health Services
  • EPO
  • MANAGED MEDICAID PLAN
  • OTHER COMMERCIAL
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medical Health
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

ST ELIZABETH MEDICAL CENTER, INC
711 Medical Village Dr, Edgewood, KY 41017

Additional Areas of Focus

Dr. Islas has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Adult Immune Thrombocytopenia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Dual-cohort, Open-label, Phase 2 Study of Brentuximab Vedotin and CHP (A+CHP) in the Frontline Treatment of Subjects With Peripheral T-cell Lymphoma (PTCL) With Less Than 10% CD30 Expression
A Dual-cohort, Open-label, Phase 2 Study of Brentuximab Vedotin and CHP (A+CHP) in the Frontline Treatment of Subjects With Peripheral T-cell Lymphoma (PTCL) With Less Than 10% CD30 Expression
Enrollment Status: Active_not_recruiting
Publish Date: September 12, 2025
Intervention Type: Drug
Study Drugs: Brentuximab vedotin, Cyclophosphamide, Doxorubicin, Prednisone
Study Phase: Phase 2
Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects
Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects
Enrollment Status: Terminated
Publish Date: August 28, 2025
Intervention Type: Drug
Study Drugs: Brentuximab, Doxorubicin, Vinblastine, Dacarbazine, Nivolumab, Filgrastim
Study Phase: Phase 2
A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Enrollment Status: Active_not_recruiting
Publish Date: August 26, 2025
Intervention Type: Drug, Other
Study Drugs: Brentuximab vedotin, Rituximab, Lenalidomide
Study Phase: Phase 3
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
Enrollment Status: Active_not_recruiting
Publish Date: May 28, 2025
Intervention Type: Drug
Study Drugs: LOXO-305, Ibrutinib, Acalabrutinib, Zanubrutinib
Study Phase: Phase 3
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Pirtobrutinib, Idelalisib, Bendamustine, Rituximab
Study Phase: Phase 3
SYMPHONY-II: A Phase II Open-Label, Multicenter Trial of Oral Tazemetostat in Combination With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma
SYMPHONY-II: A Phase II Open-Label, Multicenter Trial of Oral Tazemetostat in Combination With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma
Enrollment Status: Terminated
Publish Date: March 25, 2024
Intervention Type: Drug, Combination product
Study Drug: Tazemetostat
Study Phase: Phase 2
A Prospective Observational Study for the Long-term Follow-up of Subjects Previously Enrolled in Selected Clinical Studies of CMX001.
A Prospective Observational Study for the Long-term Follow-up of Subjects Previously Enrolled in Selected Clinical Studies of CMX001.
Enrollment Status: Terminated
Publish Date: May 17, 2019
Intervention Type: Drug
View 6 Less Clinical Trials

5 Total Publications

Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for advanced-stage classical Hodgkin lymphoma.
Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for advanced-stage classical Hodgkin lymphoma.
Journal: Blood
Published: April 08, 2024
Similar Doctors
Advanced in Primary Immunodeficiency (PID)
Dr. Ketan S. Shah
Hematology Oncology | Oncology | Hematology
Advanced in Primary Immunodeficiency (PID)
Dr. Ketan S. Shah
Hematology Oncology | Oncology | Hematology

Dayton Physicians LLC

3120 Governors Place Blvd, 
Kettering, OH 
 (51.9 miles away)
937-293-1622
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Ketan Shah is a Hematologist Oncology specialist and an Oncologist in Kettering, Ohio. Dr. Shah is rated as an Advanced provider by MediFind in the treatment of Primary Immunodeficiency (PID). His top areas of expertise are Thrombocytopenia, Breast Cancer in Men, Myelodysplastic Syndrome (MDS), Pleuropulmonary Blastoma, and Bone Marrow Aspiration. Dr. Shah is currently accepting new patients.

Experienced in Primary Immunodeficiency (PID)
Dr. James H. Essell
Hematology Oncology | Hematology | Oncology
Experienced in Primary Immunodeficiency (PID)
Dr. James H. Essell
Hematology Oncology | Hematology | Oncology

Oncology Hematology Care Inc

4777 E Galbraith Rd, Suite 1, 
Cincinnati, OH 
 (16.8 miles away)
513-751-2273
Languages Spoken:
English
See accepted insurances
Accepting New Patients

James Essell is a Hematologist Oncology specialist and a Hematologist in Cincinnati, Ohio. Dr. Essell is rated as a Distinguished provider by MediFind in the treatment of Primary Immunodeficiency (PID). His top areas of expertise are Non-Hodgkin Lymphoma, Chronic Graft Versus Host Disease (cGvHD), Graft Versus Host Disease (GvHD), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Essell is currently accepting new patients.

Advanced in Primary Immunodeficiency (PID)
Dr. Rafiullah Khan
Hematology | Oncology
Advanced in Primary Immunodeficiency (PID)
Dr. Rafiullah Khan
Hematology | Oncology

Christ Hospital Medical Specialists Ii, LLC

11140 Montgomery Rd, 
Cincinnati, OH 
 (21.8 miles away)
513-564-8580
Languages Spoken:
English
See accepted insurances

Rafiullah Khan is a Hematologist and an Oncologist in Cincinnati, Ohio. Dr. Khan is rated as a Distinguished provider by MediFind in the treatment of Primary Immunodeficiency (PID). His top areas of expertise are Multiple Myeloma, Agranulocytosis, Malabsorption, Thrombocytopenia, and Splenectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Islas's expertise for a condition
ConditionClose
    View All 10 Distinguished Conditions
    View All 29 Advanced Conditions
    View All 52 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile